W Iris Zhi1, Raymond E Baser2, Alice Kwon3, Connie Chen4, Susan Qing Li5, Lauren Piulson5, Christina Seluzicki5, Katherine S Panageas2, Steven E Harte6, Jun J Mao5, Ting Bao7,8. 1. Breast Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Epidemiology and Biostatistics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA. 4. New York University Winthrop Hospital, New York, NY, USA. 5. Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, USA. 7. Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. baot@mskcc.org. 8. Bendheim Integrative Medicine Center, 1429 First Avenue, New York, NY, 10021, USA. baot@mskcc.org.
Abstract
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect in cancer survivors. This study aimed to assess the characteristics of quantitative sensory testing (QST) and its correlation with patient-reported outcomes (PROs) in cancer patients with and without CIPN. METHODS: We conducted a cross-sectional analysis using baseline data from two clinical trials in solid tumor cancer survivors with no CIPN symptoms rated < 2 on a 0-10 Numerical Rating Scale (NRS) or moderate-to-severe CIPN rated ≥ 4 on the NRS. We collected PROs (NRS, Neuropathic Pain Scale, and Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity subscale at baseline. QST [Tactile Threshold (TT), Vibration Threshold (VT), Thermal Threshold (THT)] measurements were used to assess sensory fiber function; they were compared between patients with and without CIPN using Wilcoxon rank-sum tests. We used Spearman correlation coefficients to estimate associations between PROs and QST in all patients. RESULTS: Among 116 participants with CIPN (median NRS 5.00) and 10 participants without CIPN (median NRS 0.00), the median (interquartile range) TT was 3.84 (3.47, 4.12) and 3.53 (3.00, 3.84) in feet, respectively (p = 0.043). The median VT was 17.90 (9.42, 26.95) and 7.73 (5.94, 11.11) in feet, respectively (p = 0.001). Thermal cool threshold was 30.00 °C (28.90, 30.57) and 30.67 °C (30.57, 30.93), respectively (p = 0.007). Correlation coefficients between PROs and QST measures ranged between 0.02 and 0.50 in absolute magnitude. CONCLUSION: Patients with moderate-to-severe CIPN had significantly impaired tactile, vibratory, and thermal thresholds compared to patients without CIPN. QST correlates with PROs, suggesting CIPN symptom severity may correspond to sensory fiber functionality. QST may be incorporated into future CIPN research.
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect in cancer survivors. This study aimed to assess the characteristics of quantitative sensory testing (QST) and its correlation with patient-reported outcomes (PROs) in cancer patients with and without CIPN. METHODS: We conducted a cross-sectional analysis using baseline data from two clinical trials in solid tumor cancer survivors with no CIPN symptoms rated < 2 on a 0-10 Numerical Rating Scale (NRS) or moderate-to-severe CIPN rated ≥ 4 on the NRS. We collected PROs (NRS, Neuropathic Pain Scale, and Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity subscale at baseline. QST [Tactile Threshold (TT), Vibration Threshold (VT), Thermal Threshold (THT)] measurements were used to assess sensory fiber function; they were compared between patients with and without CIPN using Wilcoxon rank-sum tests. We used Spearman correlation coefficients to estimate associations between PROs and QST in all patients. RESULTS: Among 116 participants with CIPN (median NRS 5.00) and 10 participants without CIPN (median NRS 0.00), the median (interquartile range) TT was 3.84 (3.47, 4.12) and 3.53 (3.00, 3.84) in feet, respectively (p = 0.043). The median VT was 17.90 (9.42, 26.95) and 7.73 (5.94, 11.11) in feet, respectively (p = 0.001). Thermal cool threshold was 30.00 °C (28.90, 30.57) and 30.67 °C (30.57, 30.93), respectively (p = 0.007). Correlation coefficients between PROs and QST measures ranged between 0.02 and 0.50 in absolute magnitude. CONCLUSION: Patients with moderate-to-severe CIPN had significantly impaired tactile, vibratory, and thermal thresholds compared to patients without CIPN. QST correlates with PROs, suggesting CIPN symptom severity may correspond to sensory fiber functionality. QST may be incorporated into future CIPN research.
Authors: Miroslav Misha Backonja; Nadine Attal; Ralf Baron; Didier Bouhassira; Mark Drangholt; Peter J Dyck; Robert R Edwards; Roy Freeman; Richard Gracely; Maija H Haanpaa; Per Hansson; Samar M Hatem; Elena K Krumova; Troels S Jensen; Christoph Maier; Gerard Mick; Andrew S Rice; Roman Rolke; Rolf-Detlef Treede; Jordi Serra; Thomas Toelle; Valeri Tugnoli; David Walk; Mark S Walalce; Mark Ware; David Yarnitsky; Dan Ziegler Journal: Pain Date: 2013-06-03 Impact factor: 6.961
Authors: Jessica A Boyette-Davis; Cathy Eng; Xin S Wang; Charles S Cleeland; Gwen Wendelschafer-Crabb; William R Kennedy; Donald A Simone; Haijun Zhang; Patrick M Dougherty Journal: Clin Cancer Res Date: 2012-04-10 Impact factor: 12.531
Authors: Samah Hayek; Rikeenkumar Dhaduk; Yadav Sapkota; William E Evans; Barthelemy Diouf; Kari Bjornard; Carmen L Wilson; Melissa M Hudson; Leslie L Robison; Raja B Khan; Deo Kumar Srivastava; Kevin R Krull; Kirsten K Ness Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-09-28 Impact factor: 4.090
Authors: Laura Lorenzo-Gallego; Beatriz Arranz-Martín; Helena Romay-Barrero; Virginia Prieto-Gómez; Enrique Lluch; María Torres-Lacomba Journal: Int J Environ Res Public Health Date: 2022-03-29 Impact factor: 3.390